Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 20-year-old shared progress pictures after 2 years of using oral finasteride and oral minoxidil for hair loss. Responses included admiration and requests for more details and updates.

The user shared a 2-month progress update using topical finasteride and minoxidil for hair loss. The conversation included comments on the user's appearance and potential side effects.

OP experienced significant hair regrowth using 1 mg oral Finasteride and switched from topical to 2.5 mg oral Minoxidil, with concerns about miniaturized hairs near the hairline. OP plans to grow out their hair and is curious about future regrowth potential and hairstyle suitability.

The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.

A 32-year-old shares 2-month progress using oral finasteride, topical minoxidil, and weekly derma stamping for hair loss, noting early improvements and no side effects. Encouragement is given for continued progress.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

The conversation discusses the best vehicle for topical dutasteride, comparing Trichosol, Transcutol, and a gel version. It also mentions using Transcutol with ethanol to enhance transdermal delivery of Bimatoprost.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

A 24-year-old shared their 2-month progress using oral finasteride (1mg) four times a week, topical minoxidil (5%) daily, and ketoconazole shampoo twice a week for hair loss. They experienced initial headaches and shedding but plan to continue the regimen due to positive results.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

The user is using Minoxidil and finasteride for hair loss and is concerned about the lack of visible progress after two months, despite some users noting increased hair density. Increased shedding is considered normal and a sign of effectiveness.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

The conversation discusses the use of 0.1% latanoprost for hair regrowth, with concerns about cost and dependency. The user currently uses dutasteride and oral minoxidil and is considering adding latanoprost to their regimen.

The user reports thicker and fuller hair after using finasteride, topical minoxidil, RU58841, and dermarolling for two years. Consistent lighting is noted as important for progress pictures.

2-Deoxy-D-Ribose (2dDR) is likely ineffective for treating hair loss and performs worse than 5% minoxidil. Finasteride and minoxidil are more effective treatments.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

The conversation discusses obtaining an online EU prescription for Bimatoprost/Lumigan for hair loss without an in-person doctor visit. The user is seeking alternatives to physical consultations for this treatment.

Piroctone Olamine at 1% is recommended for reducing scalp inflammation and encouraging hair growth. The user seeks recommendations for UK shampoos/conditioners containing this ingredient.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

The user reported significant improvement in hair quality and stability using topical finasteride for two years, without side effects. They later added minoxidil, which may have further enhanced hair quality.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

A user shared progress pictures after two months of using oral finasteride and minoxidil, along with inconsistent derma rolling. Replies noted hairline improvement and good coverage, especially with afro hair.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

Minoxidil may cause dark circles and affect collagen, and Tretinoin might help counteract these effects. Users suggest caution with Tretinoin due to potential Vitamin A toxicity and recommend using it sparingly with sunscreen and moisturizer.

The conversation is about experimenting with topical exosomes for hair loss treatment, alongside microneedling, Happy Head's gel-like topical, and Ordinary's hair serum. The user also mentions the availability of treatments like latanoprost and Redensyl.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The conversation discusses recommendations for using topical melatonin for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.